{"id":98213,"date":"2026-07-06T13:43:16","date_gmt":"2026-07-06T13:43:16","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/98213\/"},"modified":"2026-07-06T13:43:16","modified_gmt":"2026-07-06T13:43:16","slug":"pharmalittle-novartis-buys-myricx-bio-gop-backs-trial-diversity","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/98213\/","title":{"rendered":"Pharmalittle: Novartis buys Myricx Bio, GOP backs trial diversity"},"content":{"rendered":"

Good morning, and welcome to a new week from STAT\u2019s London outpost, with Andrew Joseph here filling in for Mr. Pharmalot. This country is celebrating its World Cup win last night (or rather, very early this morning local time \u2014 lots of bleary-eyed people out in the neighborhood today), and I can only hope that the U.S. will be in the same place tomorrow. Yet the World Cup (and Wimbledon) can\u2019t completely distract from the news of the day, so onto the headlines we go. \u2026\u00a0<\/p>\n

Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload, Fierce Biotech<\/a> writes. The Swiss pharma company has been slower to buy into ADCs than some of its peers, but it\u2019s made its move with London-based Myricx, which is designing cancer treatments that deliver N-myristoyltransferase inhibitor (NMTi) payloads. It\u2019s a bit of a different approach from other ADCs, which Novartis predicts could tackle resistance and other limitations of existing payloads, broadening the use of ADCs across multiple tumor types.\u00a0<\/p>\n

While clinical trials got caught up in the Trump administration\u2019s attack on policies related to diversity, equity, and inclusion, congressional Republicans would like to change that, STAT<\/a> says. Last month, the Republican-controlled House passed a bill, mostly along party lines, to fund the Food and Drug Administration that was accompanied by a report that, while not legally binding, tells agency officials what congressional appropriators expected of them. The report states that it wants the FDA to continue implementing a law that requires companies to give the FDA their plans for diversifying clinical trials.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Good morning, and welcome to a new week from STAT\u2019s London outpost, with Andrew Joseph here filling in…\n","protected":false},"author":2,"featured_media":98214,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[206,30229,339],"class_list":["post-98213","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-novartis","tag-pharmalittle","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116873331172665177","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/98213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=98213"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/98213\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/98214"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=98213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=98213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=98213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}